Search research articles
Contact Us
Filters
Showing results (1-10 of 393) with videos related to
Page
of 40
Sort By:
Personality Disorders
|
July 5, 2022
Should the demonstration of improved patient outcome be necessary to overhaul diagnostic approaches?: Comment on Bach and Tracy (2022)
Mark Zimmerman
Journal of Affective Disorders
|
June 23, 2021
Using Screening Scales for Bipolar Disorder in Epidemiologic Studies: Lessons Not Yet Learned
Mark Zimmerman
The British Journal of Psychiatry : the Journal of Mental Science
|
June 3, 2016
The FDA's failure to address the lack of generalisability of antidepressant efficacy trials in product labelling
Mark Zimmerman
Personality Disorders
|
January 1, 2014
What is ironic about wanting empirical support to justify changes in diagnostic criteria? Commentary on "the ironic fate of the personality disorders in DSM-5"
Mark Zimmerman
Psychotherapy and Psychosomatics
|
April 4, 2013
Reply: To PMID 22964496
Mark Zimmerman
Essential Psychopharmacology
|
March 16, 2005
Can the findings of antidepressant efficacy trials be extrapolated to the general population of depressed patients? Interview by Dr. Frederic Flach
Mark Zimmerman
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)
|
October 13, 2011
Broadening the concept of bipolar disorder: what should be done in the face of uncertainty?
Mark Zimmerman
CNS Spectrums
|
January 13, 2017
Measures of the DSM-5 mixed-features specifier of major depressive disorder
Mark Zimmerman
The Journal of Clinical Psychiatry
|
August 25, 2022
Positive Predictive Value: A Clinician's Guide to Avoid Misinterpreting the Results of Screening Tests
Mark Zimmerman
Journal of Personality Disorders
|
April 21, 2015
Improving the Recognition of Borderline Personality Disorder in a Bipolar World
Mark Zimmerman
Page
of 40
Search research articles
Search
Showing results (1-10 of 393) with videos related to
Sort By:
Page
of 40
Personality Disorders
|
July 5, 2022
Should the demonstration of improved patient outcome be necessary to overhaul diagnostic approaches?: Comment on Bach and Tracy (2022)
Mark Zimmerman
Journal of Affective Disorders
|
June 23, 2021
Using Screening Scales for Bipolar Disorder in Epidemiologic Studies: Lessons Not Yet Learned
Mark Zimmerman
The British Journal of Psychiatry : the Journal of Mental Science
|
June 3, 2016
The FDA's failure to address the lack of generalisability of antidepressant efficacy trials in product labelling
Mark Zimmerman
Personality Disorders
|
January 1, 2014
What is ironic about wanting empirical support to justify changes in diagnostic criteria? Commentary on "the ironic fate of the personality disorders in DSM-5"
Mark Zimmerman
Psychotherapy and Psychosomatics
|
April 4, 2013
Reply: To PMID 22964496
Mark Zimmerman
Essential Psychopharmacology
|
March 16, 2005
Can the findings of antidepressant efficacy trials be extrapolated to the general population of depressed patients? Interview by Dr. Frederic Flach
Mark Zimmerman
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)
|
October 13, 2011
Broadening the concept of bipolar disorder: what should be done in the face of uncertainty?
Mark Zimmerman
CNS Spectrums
|
January 13, 2017
Measures of the DSM-5 mixed-features specifier of major depressive disorder
Mark Zimmerman
The Journal of Clinical Psychiatry
|
August 25, 2022
Positive Predictive Value: A Clinician's Guide to Avoid Misinterpreting the Results of Screening Tests
Mark Zimmerman
Journal of Personality Disorders
|
April 21, 2015
Improving the Recognition of Borderline Personality Disorder in a Bipolar World
Mark Zimmerman
Page
of 40